As per MRFR analysis, the India Glioblastoma Multiforme Market Size was estimated at 108.37 (USD Million) in 2023. The India Glioblastoma Multiforme Market Industry is expected to grow from 117.6(USD Million) in 2024 to 470.4 (USD Million) by 2035. The India Glioblastoma Multiforme Market CAGR (growth rate) is expected to be around 13.431% during the forecast period (2025 - 2035).
The India Glioblastoma Multiforme Market is characterized by significant trends that are influenced by a variety of key factors. An important factor contributing to the rise in the prevalence of brain tumors, such as glioblastoma, is the impact of environmental factors and lifestyle changes. The increased awareness of neurological disorders has encouraged a greater number of individuals to seek medical attention, resulting in earlier diagnosis and treatment. Additionally, the introduction of innovative therapies, including immunotherapy and targeted therapy, and advancements in medical technology are revolutionizing treatment approaches.Â
Additionally, the Indian government is emphasizing the improvement of healthcare infrastructure and accessibility, which will facilitate the provision of improved treatment options for patients with glioblastoma. The Indian Glioblastoma Multiforme market offers the potential to develop personalized medication that is customized to the genetic profile of patients. There is potential for the development of innovative therapies that can enhance the quality of life and survival rates as research advances. Partnerships between universities, research institutions, and pharmaceutical companies can facilitate innovation in drug development and treatment methodologies.Â
In recent years, there has been an increasing trend of clinical trials being conducted in India, which is fostering local involvement in global research endeavors. Furthermore, the utilization of digital health technologies, including telemedicine, is increasing, enabling patients in remote regions to obtain expert opinions and treatments without geographical limitations.These factors contribute to a more robust Glioblastoma Multiforme market landscape in India, indicating a vibrant path forward for both patient care and research initiatives.
Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review
Increasing Prevalence of Glioblastoma Multiforme Cases
The rising number of glioblastoma multiforme cases in India is a significant driver for the India Glioblastoma Multiforme Market Industry. Current statistics indicate that the incidence of brain tumors, particularly glioblastoma, has been increasing, with a reported rise of approximately 4.4 percent annually according to the Indian Council of Medical Research (ICMR). The ICMR has highlighted that brain tumors account for approximately 2 percent of all cancers in India, and the number of new cases is expected to exceed 20,000 every year.
Such alarming trends necessitate growing investments in both treatment options and advanced technologies. Major pharmaceutical organizations, such as Cipla and Sun Pharmaceutical Industries, are actively engaged in Research and Development (R&D) of novel therapeutic agents and delivery systems tailored to address the unique challenges posed by glioblastoma. This continuous research is fostering an environment conducive to market growth, as more effective therapies become available to combat this aggressive form of cancer.
Advancements in Medical Technology and Treatment Approaches
Rapid advancements in medical technology, including innovative surgical techniques and targeted therapies, are propelling the India Glioblastoma Multiforme Market Industry forward. Techniques such as awake craniotomy and laser interstitial thermal therapy (LITT) have shown promise in improving patient outcomes. According to the Ministry of Health and Family Welfare, the adoption of these advanced methodologies has been on the rise, leading to better surgical precision and enhanced survival rates.
Additionally, companies like Dr. Reddy's Laboratories are innovating with novel chemotherapy alongside precision medicine strategies, which aim to tailor treatments to the genetic profiles of glioblastoma patients. This level of customization in treatment regimens caters to the specific needs of individuals, thereby improving the quality of healthcare in India and contributing to the growth of the market.
Government Initiatives and Support for Cancer Treatment
The Indian government has been increasingly supportive of cancer research, which directly influences the India Glioblastoma Multiforme Market Industry. Initiatives such as the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS) have led to improved awareness and increased resources allocated for cancer treatment and research. The government's push for public-private partnerships in health infrastructure enhances access to novel treatment options.
A 2020 report from the Ministry of Health estimated that cancer-related healthcare infrastructure investments would reach approximately INR 25 billion over five years. This investment supports advanced therapies and paves the way for more companies, such as Zydus Cadila, to introduce innovative treatment solutions, ultimately benefiting glioblastoma patients in India.
The Treatment Type segment of the India Glioblastoma Multiforme Market represents a crucial aspect of the overall management and care of patients suffering from this aggressive form of brain cancer. The approach to treatment is often multi-faceted, incorporating various methodologies to combat the disease and enhance patient outcomes. Surgery, as a primary intervention, plays a pivotal role in the initial management of glioblastoma, with the aim of reducing tumor mass and potentially improving prognosis. It typically involves resecting as much of the tumor as possible, and is often complemented by additional treatment modalities to ensure comprehensive care.
Radiation Therapy remains an integral component in the overall treatment framework, as it is utilized post-surgery to target residual cancer cells, thereby minimizing the risk of recurrence. This method employs high-energy waves to obliterate cancerous cells and is widely adopted due to its effectiveness in enhancing patient survival rates.Chemotherapy contributes significantly to the treatment landscape, offering a systemic approach designed to target cancer cells throughout the body. Typically administered through various regimens, its role in conjunction with surgery and radiation is to tackle cells that may not have been removed in surgical procedures. Furthermore, advancing therapies in Immunotherapy are emerging, leveraging the body’s immune system to recognize and fight glioblastoma cells, thus showcasing a new frontier in the treatment paradigm.
Tumor Treating Field (TTF) Therapy, although more novel, is gaining traction for its non-invasive method that utilizes electric fields to disrupt the division of cancer cells. This technique underscores the trend towards integrating technology in treatment protocols and illustrates the industry's direction towards innovative solutions. Additionally, other treatments may encompass novel drug therapies and targeted treatments, illustrating the dynamic nature of the India Glioblastoma Multiforme Market.Overall, these treatment types are characterized by their interdependence and complementary roles in managing glioblastoma, reflecting the significant market trends driven by advancements in medical technology, an increasing focus on individualized treatment approaches, and ongoing Research and Development efforts.Â
Challenges remain, particularly in terms of accessibility and affordability of advanced therapy options. Yet, the landscape is evolving to incorporate more effective strategies and resources for improving patient care in India. The collective impact of these treatment modalities underlines the commitment within the healthcare sector to enhance outcomes for patients battling glioblastoma multiforme, making significant strides in what has historically been a daunting health challenge.
Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review
The end-user segment of the India Glioblastoma Multiforme Market is characterized by a diverse range of healthcare settings, including Hospitals and Clinics, Ambulatory Surgical Centers, and Others. Hospitals and Clinics typically play a pivotal role in the diagnosis and treatment of glioblastoma multiforme due to their extensive resources and specialized medical professionals, thereby serving as primary treatment hubs for patients. Ambulatory Surgical Centers have gained significance as they provide more cost-effective outpatient services for minor surgical interventions, aligning with the growing trend toward minimally invasive procedures in cancer care.
This segment is witnessing a shift as healthcare costs rise and patients seek more accessible treatment options. The Others category, which encompasses various healthcare facilities, also contributes to the market dynamics by catering to specific patient needs and providing supportive care services. Collectively, these settings significantly impact the India Glioblastoma Multiforme Market by influencing patient treatment pathways and overall healthcare outcomes, highlighting a robust engagement with innovative treatment modalities and advanced technologies in oncology.
This segment's importance is further reflected in the growing emphasis on improving patient experiences and outcomes within the Indian healthcare landscape.
India Glioblastoma Multiforme Market Key Players and Competitive Insights:
The India Glioblastoma Multiforme Market is a rapidly evolving segment within the healthcare industry, driven by an increasing prevalence of glioblastoma as one of the most aggressive forms of brain cancer. Companies in this market are focused on developing innovative treatment options, including targeted therapies and immunotherapies, to improve patient outcomes. The competitive landscape features several key players who leverage advancements in research and development, partnerships, and strategic collaborations to enhance their market presence. As the healthcare infrastructure in India expands and research capabilities improve, the market is expected to attract more investment, fostering additional competition and ultimately benefiting patients through access to novel therapies.
AstraZeneca has established a notable presence in the India Glioblastoma Multiforme Market by focusing on innovative treatment solutions and patient-centric approaches. The company has a strong emphasis on research and development, with a dedicated pipeline geared towards neurological disorders, including glioblastoma. AstraZeneca benefits from its robust global infrastructure, which is complemented by its initiatives in India, allowing it to effectively navigate regulatory landscapes and provide tailored therapies to meet local health needs. Their efforts in fostering educational and awareness campaigns about glioblastoma signify their commitment not only to treatment but also to patient support and community engagement, strengthening their market position further.
Roche has positioned itself as a significant player within the India Glioblastoma Multiforme Market through its comprehensive portfolio of oncology products and commitment to personalized medicine. The company’s key products targeting glioblastoma include groundbreaking therapies that leverage advanced genetic targeting capabilities. Roche's strengths are greatly enhanced by its clinical trial capabilities and collaborations with local research institutions, which allow for the swift translation of research into practice. Mergers and acquisitions have also played a role in strengthening Roche's offerings, providing access to innovative technologies and treatment methodologies.Â
Additionally, Roche's sustained investment in India reflects its dedication to expanding its footprint and improving patient access to cutting-edge treatments, enabling the company to continue growing its influence in this competitive market landscape.
Key Companies in the India Glioblastoma Multiforme Market Include:
India Glioblastoma Multiforme Market Industry Developments
Recent developments in the India Glioblastoma Multiforme Market have been noteworthy, particularly regarding advancements in treatments and initiatives by key pharmaceutical companies. AstraZeneca and Roche continue to enhance their portfolios with innovative therapies aimed at tackling this aggressive form of brain cancer. In September 2023, Merck and Co. announced promising results from their latest clinical trials, potentially expanding their presence in the Indian market. Growth in the market valuation of companies like Amgen and Bayer is significantly impacting the landscape, reflecting an increasing focus on Research and Development for novel drugs.
Moreover, in July 2023, Celgene secured a strategic partnership with local firms to bolster its chemotherapy options, which indicates a growing trend towards collaboration in the Indian healthcare sector. The market is projected to see a compound annual growth rate of approximately 8% over the next few years, driven by rising incidence rates and advancements in medical technology. Historical events, such as Bristol Myers Squibb's introduction of a new treatment regimen in March 2022, further illuminate the dynamics within the India Glioblastoma Multiforme Market, along with increasing government initiatives to improve cancer care and patient access to innovative therapies in the country.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 108.37(USD Million) |
| MARKET SIZE 2024 | 117.6(USD Million) |
| MARKET SIZE 2035 | 470.4(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 13.431% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | AstraZeneca, Roche, Merck & Co, Amgen, Bayer, Celgene, Bristol Myers Squibb, Sanofi, Eli Lilly, Genentech, AbbVie, Mylan, Novartis, Pfizer, Teva Pharmaceutical Industries |
| SEGMENTS COVERED | Treatment Type, End User |
| KEY MARKET OPPORTUNITIES | Innovative treatment modalities, Increasing diagnosis rates, Growing awareness and education, Rising investment in R&D, Expanding telemedicine solutions |
| KEY MARKET DYNAMICS | increasing disease prevalence, rising healthcare expenditure, growing research funding, advancements in treatment options, awareness and education initiatives |
| COUNTRIES COVERED | India |
Frequently Asked Questions (FAQ) :
The India Glioblastoma Multiforme Market is expected to be valued at 117.6 million USD by 2024.
By 2035, the India Glioblastoma Multiforme Market is projected to reach a value of 470.4 million USD.
The expected compound annual growth rate (CAGR) for the market is 13.431 percent from 2025 to 2035.
In 2024, Surgery is projected to have the largest market share at approximately 32.3 million USD.
The market size for chemotherapy in the India Glioblastoma Multiforme Market is expected to be 135.2 million USD by 2035.
Major players include AstraZeneca, Roche, Merck & Co, Amgen, and Bayer, among others.
Immunotherapy is expected to be valued at 14.2 million USD in the India Glioblastoma Multiforme Market by 2024.
Radiation Therapy is projected to reach a market value of 114.5 million USD by 2035.
Emerging trends include advancements in immunotherapy and personalized medicine for glioblastoma treatment.
The India Glioblastoma Multiforme Market is anticipated to experience significant growth over the next decade, driven by technological advancements and increasing prevalence of the disease.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
